Efectividad del tratamiento y manejo de la glomerulonefritis membranosa en pacientes adultos

Abstract

Membranous glomerulonephritis (MGN) is a chronic renal pathology that affects the glomeruli, which are the structures that filter blood in the kidneys. Timely treatment and proper management of membranous nephropathy in adult patients are essential to improve their quality of life. Objective: To describe the most effective therapeutic approaches and factors that may influence the response to treatment for early diagnosis and management of membranous glomerulonephritis. Material and methods: A descriptive narrative-type study was conducted by systematic data collection, in which a representative sample of scientific research relevant to the treatment and management of the disease from 2019 to 2023 was selected. Results: Treatment of membranous glomerulonephritis in low-risk patients is based on using ARA II or ACEI to control blood pressure and reduce proteinuria to reduce the relapse rate of the disease by 20%. Whether there is no response to therapy, more aggressive options such as immunosuppressive treatment are considered, which increases total remission by 73% and reduces the risk of presenting end-stage renal disease by 22%. Conclusions: The effectiveness of therapy for membranous glomerulonephritis relies on combining immunosuppressive therapy with steroids and alkylating agents to prevent treatment intolerance by nephrotic patients and reduce relapses of membranous nephropathy.